Key Highlights
- Retension priced an upsized IPO of 3,750,000 shares at $12.00 for $45.0 million gross, closing October 13.
- RTN-001's Phase 2b hypertension trial began in October 2025; initial data are expected in the first half of 2027.
- Going concern doubt appears in the 2025 audit report; the company expects post-IPO cash to last at least 21 months.
- Net loss for the six months ended June 30, 2026 was $7.5 million, up from $1.9 million a year earlier.
Retension Pharmaceuticals (NASDAQ:RTSN) shares were trading near their 52-week high at USD 18.48 on October 19, 2026, up 31.34%. The clinical-stage company has been public for only days: it priced its initial public offering on October 8 and closed it on October 13. The filings show one drug candidate, a Phase 2b hypertension trial and a set of cautions that sit alongside the new capital.
An upsized offering and a reshaped share count
Retension sold 3,750,000 common shares at $12.00 each, for gross proceeds of $45.0 million before underwriting discounts and expenses. The underwriters hold a 30-day option on up to 562,500 more shares. The shares were expected to begin trading on the Nasdaq Capital Market on October 9, and the Form 8-K reports a closing on October 13.
A 1-for-6.21 reverse stock split took effect on October 2, and all convertible preferred stock was set to convert into 3,774,119 common shares immediately before closing. The prospectus puts shares outstanding after the offering at 8,331,599. Proceeds and existing cash are meant to complete the Phase 2b trial and to prepare for and advance a planned Phase 3 trial in uncontrolled hypertension, with the remainder for general corporate purposes.
Losses, a going concern paragraph and other cautions
Cash and cash equivalents were $13.5 million at June 30, 2026, and the accumulated deficit was $15.8 million. Net loss for the six months ended June 30 was $7.5 million, up from $1.9 million a year earlier, with research and development expense of $6.2 million versus $1.2 million.
The auditor's report on the 2025 financial statements includes a going concern explanatory paragraph, and management concluded that, as of the interim statements' issuance, resources were insufficient to fund its operating plan for about twelve months. The prospectus also says net proceeds and existing cash should fund operations for at least 21 months from the prospectus date.
Retension also restated its 2025 results after correcting how advance payments to a contract research organization were recorded: they had been expensed when paid rather than booked as prepaid expenses. The restated 2025 net loss was $6.3 million. The company also identified a material weakness in the design of its internal control over financial reporting. Management time is another disclosed risk: the chief executive and chief scientific officer hold outside roles at affiliated companies and currently devote about 40 and 20 hours a week to the company, with both expected to work at least 40 hours a week once the offering closes.
RTN-001, the Phase 2b trial and what comes next
RTN-001 is a once-daily, oral, small-molecule PDE-5 inhibitor designed to enhance nitric oxide signaling and engineered for greater bioavailability and central arterial distribution than first-generation drugs in the class. It is being developed for uncontrolled and resistant hypertension and has not been approved by the FDA. Its earlier developer ran nine completed trials in 243 participants with no drug-related serious adverse events reported, though a 40-patient Phase 2 pilot was not powered for statistical significance.
The Phase 2b dose-ranging study began in October 2025. It is randomized, multicenter, double-blind and placebo-controlled, and it enrolls adults with uncontrolled hypertension who take two to five blood pressure medicines. The primary endpoint is the change in office-seated systolic blood pressure at week 4 versus placebo. The company expects initial data in the first half of 2027 and plans a Phase 3 trial, both subject to the clinical, regulatory and financing risks in the prospectus.
Rights to RTN-001 come through a sublicense chain that traces to Kadmon, a Sanofi subsidiary, and royalties will be owed to Kadmon if the drug is commercialized. The licensed composition-of-matter patent nominally expires in 2027, and the company says a polymorph patent it owns extends protection to at least 2044.






Please wait processing your request...